Plasmacytoid dendritic cell-based cancer vaccines
Eric Halioua, PDC*line Pharma, Liege, Belgium, provides an overview of PDC*line, a novel cell line derived from plasmacytoid dendritic cells (PDCs) in the bones of patients with leukemia. The cell line is more potent than allogeneic or autologous myeloid cells and are not rejected in humans. He additionally highlights the ease of manufacturing cancer vaccines from PDC*line due to the consistency of the cell line. This interview was conducted during Meeting on the Mediterranean 2022.
Видео Plasmacytoid dendritic cell-based cancer vaccines канала VJRegenMed
Видео Plasmacytoid dendritic cell-based cancer vaccines канала VJRegenMed
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![CAR-T trials to watch in China](https://i.ytimg.com/vi/g-dN3U2Ht9U/default.jpg)
![Exploring the potential role of CD7-targeting CAR-T cells in T-ALL](https://i.ytimg.com/vi/YlMw43TyJHQ/default.jpg)
![Current developments in cell therapies for solid tumors](https://i.ytimg.com/vi/QITTCJh9Fvo/default.jpg)
![Tabelecleucel in EBV-associated PTLD](https://i.ytimg.com/vi/8JcXIlfI-q8/default.jpg)
![Challenges in decentralized manufacturing systems](https://i.ytimg.com/vi/T3PBj8gYXH8/default.jpg)
![PiggyBac Transposon-generated CAR T-cells in solid tumors](https://i.ytimg.com/vi/UZ1FNxol_EM/default.jpg)
![Nerve regeneration with polyhydroxyalkanoate-based conduits](https://i.ytimg.com/vi/5Iv5tFCWmt0/default.jpg)
![LUMEVOQ gene therapy for LHON](https://i.ytimg.com/vi/ZICV7g0pPno/default.jpg)
![Harnessing lipid-specific TCRs to target CD1c-expressing leukemia](https://i.ytimg.com/vi/WH1CmN9pOtw/default.jpg)
![EV-based therapies for myocardial infarction](https://i.ytimg.com/vi/xmCwbtvybxo/default.jpg)
![Paige Bischoff, Senior VP, Public Affairs, Alliance for Regenerative Medicine](https://i.ytimg.com/vi/x34AXUWTAZI/default.jpg)
![The changing landscape of hospital-based cell and gene therapy manufacturing](https://i.ytimg.com/vi/ewPHBOWF2ME/default.jpg)
![Increasing manufacturing capabilities for gene therapies](https://i.ytimg.com/vi/cdzjk2TvcIQ/default.jpg)
![Developing gene therapies for GJB2 gene related hearing loss](https://i.ytimg.com/vi/ZkRtcwnfNvs/default.jpg)
![Progression of CAR-T trials in China](https://i.ytimg.com/vi/__VdZLVS0bA/default.jpg)
![Addressing supply chain issues in clinical trials](https://i.ytimg.com/vi/Ha3wm2ZfevE/default.jpg)
![IL-1Ra gene therapy for knee OA: interim Phase I results](https://i.ytimg.com/vi/sGl5q1-EvUM/default.jpg)
![Enhancing AAV gene therapy in children with inborn errors of metabolism](https://i.ytimg.com/vi/XJEA-vlmwIM/default.jpg)
![SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS](https://i.ytimg.com/vi/adXUZr--4ok/default.jpg)
![The past, present and future of AAV vectors](https://i.ytimg.com/vi/18UhN4mrjZU/default.jpg)